About this trial
Addictive full-agonist opioids, like oxycodone and hydrocodone, are often used to treat pain after surgery. However, these full-agonist opioids can be very addictive. After ankle fracture surgery, about 1 in 5 patients that did not take opioids before surgery become addicted to opioids after surgery. Buprenorphine is an opioid with unique properties that may offer a way to reduce the number of patients that become addicted to opioids after surgery. Buprenorphine has good analgesic (painkilling) effects. It is also thought to be less addictive and cause less of a high than full-agonist opioids, like oxycodone and hydrocodone. This project's goal is to determine if transdermal buprenorphine can safely and effectively control pain after ankle fracture surgery. This study will be a pilot study, which sets the stage for future studies that investigate whether buprenorphine can reduce the rate that patients become addicted to opioids after surgery. This study's multidisciplinary team will divide patients into two groups. Participants in one group will be treated with a 7-day transdermal buprenorphine patch (where the buprenorphine is slowly absorbed through the skin over 7 days). Participants in the other group will be treated with a placebo patch. A placebo has no drug in it, it just looks like the buprenorphine patch. Aside from the buprenorphine patch or placebo patch, both groups' pain management plans will be the same as if they were not in the study. Over the first week after surgery, the investigators will measure the amount of full-agonist opioids (for example, oxycodone or hydrocodone) that participants consume, participants' pain scores, the frequency of side effects related to opioids, and the number of calls and patient portal messages to the clinic for uncontrolled pain. The investigators will also assess whether participants are continuing to use opioids 3 months after surgery for pain related to their ankle fracture.
Eligibility criteria
Qualifiers
Patient is 18 years of age or older
Patient is undergoing single stage ORIF of an ankle fracture
Patient is English-speaking
Disqualifiers
Patient is under 18 years of age
Patient's ankle fracture is treated with external fixation
Patient has a concomitant osseous or visceral injury
Patient has a history of opioid use disorder or a current diagnosis of opioid use disorder
Trial design
Treatments tested in this trial
- Buprenorphine Transdermal System
- Placebo Patch
Treatment groups
Sponsors and collaborators
Jenna-Leigh Wilson
Lead sponsor
Washington University School of Medicine
Sponsor institution
The Foundation for Barnes-Jewish Hospital
Collaborator
Washington University Institute of Clinical and Translational Sciences
Collaborator